<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Prevalence and prognosis of Alzheimer&apos;s disease at the mild cognitive impairment stage</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>PhD</roleName><forename type="first">Stephanie</forename><forename type="middle">J B</forename><surname>Vos</surname></persName>
							<email>s.vos@maastrichtuniversity.nl</email>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Psychiatry and Neuropsychology</orgName>
								<orgName type="department" key="dep2">School for Mental Health and Neuroscience</orgName>
								<orgName type="institution" key="instit1">Maastricht University</orgName>
								<orgName type="institution" key="instit2">Alzheimer Centre Limburg</orgName>
								<address>
									<settlement>Maastricht</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Frans</forename><surname>Verhey</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Psychiatry and Neuropsychology</orgName>
								<orgName type="department" key="dep2">School for Mental Health and Neuroscience</orgName>
								<orgName type="institution" key="instit1">Maastricht University</orgName>
								<orgName type="institution" key="instit2">Alzheimer Centre Limburg</orgName>
								<address>
									<settlement>Maastricht</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Lutz</forename><surname>Fro</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Geriatric Psychiatry</orgName>
								<orgName type="department" key="dep2">Zentralinstitut fu ¨r Seelische Gesundheit</orgName>
								<orgName type="institution">University of Heidelberg</orgName>
								<address>
									<settlement>Mannheim</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Johannes</forename><surname>Kornhuber</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Psychiatry and Psychotherapy</orgName>
								<orgName type="institution">Friedrich-Alexander University of Erlangen</orgName>
								<address>
									<settlement>Erlangen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jens</forename><surname>Wiltfang</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Department of Psychiatry and Psychotherapy</orgName>
								<orgName type="institution" key="instit1">University Medical Centre (UMG)</orgName>
								<orgName type="institution" key="instit2">Georg-August-University</orgName>
								<address>
									<addrLine>Go ¨ttingen</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wolfgang</forename><surname>Maier</surname></persName>
							<affiliation key="aff5">
								<orgName type="department" key="dep1">Department of Psychiatry and Psychotherapy</orgName>
								<orgName type="department" key="dep2">German Centre for Neurodegenerative Diseases (DZNE)</orgName>
								<orgName type="institution">University of Bonn</orgName>
								<address>
									<settlement>Bonn</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Oliver</forename><surname>Peters</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Psychiatry and Psychotherapy</orgName>
								<address>
									<addrLine>Charite ´Berlin</addrLine>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Eckart</forename><surname>Ru</surname></persName>
							<affiliation key="aff7">
								<orgName type="department">Department of Psychiatry and Psychotherapy</orgName>
								<orgName type="institution">University of Go ¨ttingen</orgName>
								<address>
									<addrLine>Go ¨ttingen</addrLine>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Flavio</forename><surname>Nobili</surname></persName>
							<affiliation key="aff8">
								<orgName type="department" key="dep1">Clinical Neurophysiology Service</orgName>
								<orgName type="department" key="dep2">Department of Neurosciences, Ophthalmology and Genetics</orgName>
								<orgName type="institution">University of Genoa</orgName>
								<address>
									<settlement>Genoa</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Silvia</forename><surname>Morbelli</surname></persName>
							<affiliation key="aff9">
								<orgName type="department" key="dep1">Nuclear Medicine</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine</orgName>
								<orgName type="institution">University of Genoa</orgName>
								<address>
									<settlement>Genoa</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Giovanni</forename><forename type="middle">B</forename><surname>Frisoni</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">IRCCS San Giovanni di Dio Fatebenefratelli</orgName>
								<address>
									<settlement>Brescia</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff11">
								<orgName type="institution">University Hospitals and University of Geneva</orgName>
								<address>
									<settlement>Geneva</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alexander</forename><surname>Drzezga</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">Department of Nuclear Medicine</orgName>
								<orgName type="institution">University of Cologne</orgName>
								<address>
									<settlement>Cologne</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mira</forename><surname>Didic</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Service de Neurologie et Neuropsychologie</orgName>
								<orgName type="institution">Aix Marseille Universite ´</orgName>
								<address>
									<addrLine>Po ˆle de neurosciences cliniques</addrLine>
									<postCode>AP-HM</postCode>
									<settlement>Timone</settlement>
								</address>
							</affiliation>
							<affiliation key="aff14">
								<orgName type="institution">INS UMR_S 1106</orgName>
								<address>
									<postCode>13005</postCode>
									<settlement>Marseille</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bart</forename><forename type="middle">N M</forename><surname>Van Berckel</surname></persName>
							<affiliation key="aff15">
								<orgName type="department">Department of Nuclear Medicine and PET Research</orgName>
								<orgName type="institution">VU University Medical CentRE</orgName>
								<address>
									<settlement>Amsterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Andrew</forename><surname>Simmons</surname></persName>
							<affiliation key="aff16">
								<orgName type="department" key="dep1">Department of Neuroimaging</orgName>
								<orgName type="department" key="dep2">Centre for Neuroimaging Science</orgName>
								<orgName type="department" key="dep3">Institute of Psychiatry</orgName>
								<orgName type="institution">King&apos;s College London</orgName>
								<address>
									<settlement>London</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Hilkka</forename><surname>Soininen</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Institute of Clinical Medicine</orgName>
								<orgName type="institution">University of Eastern Finland and Neurocenter</orgName>
								<address>
									<settlement>Neurology, Neurology</settlement>
								</address>
							</affiliation>
							<affiliation key="aff18">
								<orgName type="institution">Kuopio University Hospital</orgName>
								<address>
									<settlement>Kuopio</settlement>
									<country key="FI">Finland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Iwona</forename><surname>Kloszewska</surname></persName>
							<affiliation key="aff19">
								<orgName type="institution">Medical University of Lodz</orgName>
								<address>
									<settlement>Lodz</settlement>
									<country key="PL">Poland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Patrizia</forename><surname>Mecocci</surname></persName>
							<affiliation key="aff20">
								<orgName type="department">Institute of Gerontology and Geriatrics</orgName>
								<orgName type="institution">University of Perugia</orgName>
								<address>
									<settlement>Perugia</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Magda</forename><surname>Tsolaki</surname></persName>
							<affiliation key="aff21">
								<orgName type="department" key="dep1">Memory and Dementia Center</orgName>
								<orgName type="department" key="dep2">3rd Department of Neurology</orgName>
								<orgName type="institution" key="instit1">Aristotle University of Thessaloniki</orgName>
								<orgName type="institution" key="instit2">&quot;G Papanicolaou&quot; General Hospital</orgName>
								<address>
									<settlement>Thessaloniki</settlement>
									<country key="GR">Greece</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Bruno</forename><surname>Vellas</surname></persName>
							<affiliation key="aff22">
								<orgName type="laboratory">UMR INSERM 1027</orgName>
								<orgName type="institution">CHU Toulouse</orgName>
								<address>
									<settlement>Toulouse</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Simon</forename><surname>Lovestone</surname></persName>
							<affiliation key="aff23">
								<orgName type="department">Department of Psychiatry</orgName>
								<orgName type="institution">University of Oxford</orgName>
								<address>
									<settlement>Oxford</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Cristina</forename><surname>Muscio</surname></persName>
							<affiliation key="aff10">
								<orgName type="institution">IRCCS San Giovanni di Dio Fatebenefratelli</orgName>
								<address>
									<settlement>Brescia</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff24">
								<orgName type="department">Fondazione Europea Ricerca Biomedica (FERB)</orgName>
								<address>
									<addrLine>Centro di Eccellenza Alzheimer, Ospedale Briolini</addrLine>
									<settlement>Gazzaniga, Bergamo</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff25">
								<orgName type="department">Department of Molecular and Translational Medicine</orgName>
								<orgName type="institution">University of Brescia</orgName>
								<address>
									<settlement>Brescia</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sanna-Kaisa</forename><surname>Herukka</surname></persName>
							<affiliation key="aff17">
								<orgName type="department">Institute of Clinical Medicine</orgName>
								<orgName type="institution">University of Eastern Finland and Neurocenter</orgName>
								<address>
									<settlement>Neurology, Neurology</settlement>
								</address>
							</affiliation>
							<affiliation key="aff18">
								<orgName type="institution">Kuopio University Hospital</orgName>
								<address>
									<settlement>Kuopio</settlement>
									<country key="FI">Finland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Eric</forename><surname>Salmon</surname></persName>
							<affiliation key="aff26">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution" key="instit1">Memory Clinic</orgName>
								<orgName type="institution" key="instit2">CHU Lie `ge</orgName>
								<address>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
							<affiliation key="aff27">
								<orgName type="department">Cyclotron Research Centre</orgName>
								<orgName type="institution">University of Lie `ge</orgName>
								<address>
									<addrLine>Lie `ge</addrLine>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Christine</forename><surname>Bastin</surname></persName>
							<affiliation key="aff27">
								<orgName type="department">Cyclotron Research Centre</orgName>
								<orgName type="institution">University of Lie `ge</orgName>
								<address>
									<addrLine>Lie `ge</addrLine>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Anders</forename><surname>Wallin</surname></persName>
							<affiliation key="aff28">
								<orgName type="department" key="dep1">Department of Psychiatry and Neurochemistry</orgName>
								<orgName type="department" key="dep2">Institute for Neuroscience and Physiology</orgName>
								<orgName type="department" key="dep3">Sahlgrenska Academy</orgName>
								<orgName type="institution">University of Gothenburg</orgName>
								<address>
									<settlement>Gothenburg</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Arto</forename><surname>Nordlund</surname></persName>
							<affiliation key="aff28">
								<orgName type="department" key="dep1">Department of Psychiatry and Neurochemistry</orgName>
								<orgName type="department" key="dep2">Institute for Neuroscience and Physiology</orgName>
								<orgName type="department" key="dep3">Sahlgrenska Academy</orgName>
								<orgName type="institution">University of Gothenburg</orgName>
								<address>
									<settlement>Gothenburg</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Alexandre</forename><surname>De Mendonc</surname></persName>
							<affiliation key="aff29">
								<orgName type="department" key="dep1">Institute of Molecular Medicine</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="institution">University of Lisbon</orgName>
								<address>
									<country key="PT">Portugal</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Dina</forename><surname>Silva</surname></persName>
							<affiliation key="aff29">
								<orgName type="department" key="dep1">Institute of Molecular Medicine</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="institution">University of Lisbon</orgName>
								<address>
									<country key="PT">Portugal</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Isabel</forename><surname>Santana</surname></persName>
							<affiliation key="aff30">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">Coimbra University Hospital</orgName>
								<address>
									<settlement>Coimbra</settlement>
									<country key="PT">Portugal</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Raquel</forename><surname>Lemos</surname></persName>
							<affiliation key="aff31">
								<orgName type="department">Faculty of Psychology and Educational Sciences</orgName>
								<orgName type="institution">University of Coimbra</orgName>
								<address>
									<settlement>Coimbra</settlement>
									<country key="PT">Portugal</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sebastiaan</forename><surname>Engelborghs</surname></persName>
							<affiliation key="aff0">
								<orgName type="institution">The Alzheimer&apos;s Disease Neuroimaging Initiative</orgName>
							</affiliation>
							<affiliation key="aff32">
								<orgName type="department">Institute Born-Bunge</orgName>
								<orgName type="laboratory" key="lab1">Reference Centre for Biological Markers of Dementia (BIODEM)</orgName>
								<orgName type="laboratory" key="lab2">Laboratory of Neurochemistry and Behaviour</orgName>
								<orgName type="institution">University of Antwerp</orgName>
								<address>
									<settlement>Antwerp</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
							<affiliation key="aff33">
								<orgName type="department">Department of Neurology and Memory Clinic</orgName>
								<orgName type="institution">Hospital Network Antwerp, Middelheim and Hoge Beuken</orgName>
								<address>
									<settlement>Antwerp</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stefan</forename><surname>Van Der Mussele</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yvonne</forename><surname>Freund-Levi</surname></persName>
							<affiliation key="aff34">
								<orgName type="department" key="dep1">Department of Neurobiology, Caring Sciences and Society (NVS)</orgName>
								<orgName type="department" key="dep2">Division of Clinical Geriatrics</orgName>
								<orgName type="institution">Karolinska Institutet</orgName>
							</affiliation>
							<affiliation key="aff35">
								<orgName type="department">Department of Geriatric Medicine</orgName>
								<orgName type="institution">Karolinska University Hospital Huddinge</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">A ˚sa</forename><forename type="middle">K</forename><surname>Wallin</surname></persName>
							<affiliation key="aff36">
								<orgName type="department">Clinical Sciences Malmo ¨</orgName>
								<orgName type="institution" key="instit1">Lund University</orgName>
								<orgName type="institution" key="instit2">Clinical Memory Research Unit</orgName>
								<address>
									<settlement>Lund</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Harald</forename><surname>Hampel</surname></persName>
							<affiliation key="aff37">
								<orgName type="department" key="dep1">Centre des Maladies Cognitives et Comportementales</orgName>
								<orgName type="department" key="dep2">Institut du Cerveau et de la Moelle e ´pinie `re</orgName>
								<orgName type="institution">Universite ´Pierre et Marie Curie-Paris 6</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff38">
								<orgName type="institution">AP-HP</orgName>
								<address>
									<addrLine>Ho ˆpital de la Salpe ˆtrie `re</addrLine>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wiesje</forename><surname>Van Der Flier</surname></persName>
							<affiliation key="aff39">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution" key="instit1">Alzheimer Centre</orgName>
								<orgName type="institution" key="instit2">Neuroscience Campus Amsterdam</orgName>
								<orgName type="institution" key="instit3">VU University Medical Center</orgName>
								<address>
									<settlement>Amsterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Philip</forename><surname>Scheltens</surname></persName>
							<affiliation key="aff39">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution" key="instit1">Alzheimer Centre</orgName>
								<orgName type="institution" key="instit2">Neuroscience Campus Amsterdam</orgName>
								<orgName type="institution" key="instit3">VU University Medical Center</orgName>
								<address>
									<settlement>Amsterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pieter</forename><forename type="middle">Jelle</forename><surname>Visser</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Psychiatry and Neuropsychology</orgName>
								<orgName type="department" key="dep2">School for Mental Health and Neuroscience</orgName>
								<orgName type="institution" key="instit1">Maastricht University</orgName>
								<orgName type="institution" key="instit2">Alzheimer Centre Limburg</orgName>
								<address>
									<settlement>Maastricht</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
							<affiliation key="aff39">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution" key="instit1">Alzheimer Centre</orgName>
								<orgName type="institution" key="instit2">Neuroscience Campus Amsterdam</orgName>
								<orgName type="institution" key="instit3">VU University Medical Center</orgName>
								<address>
									<settlement>Amsterdam</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff40">
								<orgName type="department" key="dep1">Department of Psychiatry and Neuropsychology</orgName>
								<orgName type="department" key="dep2">School for Mental Health and Neuroscience</orgName>
								<orgName type="institution">Maastricht University</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff41">
								<orgName type="institution">Alzheimer Centre Limburg</orgName>
								<address>
									<postBox>P.O. Box 616</postBox>
									<postCode>6200 MD</postCode>
									<settlement>Maastricht</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Prevalence and prognosis of Alzheimer&apos;s disease at the mild cognitive impairment stage</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">3EA53BF775B5B871A7275207210685AF</idno>
					<idno type="DOI">10.1093/brain/awv055</idno>
					<note type="submission">Received September 17, 2014. Revised November 27, 2014. Accepted December 15, 2014. Advance Access publication February 18, 2015</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:11+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Alzheimer&apos;s disease</term>
					<term>MCI</term>
					<term>biomarkers</term>
					<term>diagnostic criteria</term>
					<term>prognosis</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>We compared the prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage according to these criteria.</s><s>Subjects with mild cognitive impairment (n = 1607), 766 of whom had both amyloid and neuronal injury markers, were recruited from 13 cohorts.</s><s>We used cognitive test performance and available biomarkers to classify subjects as prodromal Alzheimer's disease according to International Working Group-1 and International Working Group-2 criteria and in the high Alzheimer's disease likelihood group, conflicting biomarker groups (isolated amyloid pathology or suspected non-Alzheimer pathophysiology), and low Alzheimer's disease likelihood group according to the National Institute of Ageing-Alzheimer Association criteria.</s><s>Outcome measures were the proportion of subjects with Alzheimer's disease at the mild cognitive impairment stage and progression to Alzheimer's disease-type dementia.</s><s>We performed survival analyses using Cox proportional hazards models.</s><s>According to the International Working Group-1 criteria, 850 (53%) subjects had prodromal Alzheimer's disease.</s><s>Their 3-year progression rate to Alzheimer's disease-type dementia was 50% compared to 21% for subjects without prodromal Alzheimer's disease.</s><s>According to the International Working Group-2 criteria, 308 (40%) subjects had prodromal Alzheimer's disease.</s><s>Their 3-year progression rate to Alzheimer's disease-type dementia was 61% compared to 22% for subjects without prodromal Alzheimer's disease.</s><s>According to the National Institute of Ageing-Alzheimer Association criteria, 353 (46%) subjects were in the high Alzheimer's disease likelihood group, 49 (6%) in the isolated amyloid pathology group, 220 (29%) in the suspected non-Alzheimer pathophysiology group, and 144 (19%) in the low Alzheimer's disease likelihood group.</s><s>The 3-year progression rate to Alzheimer's disease-type dementia was 59% in the high Alzheimer's disease likelihood group, 22% in the isolated amyloid pathology group, 24% in the suspected non-Alzheimer pathophysiology group, and 5% in the low Alzheimer's disease likelihood group.</s><s>Our findings support the use of the proposed research criteria to identify Alzheimer's disease at the mild cognitive impairment stage.</s><s>In clinical settings, the use of both amyloid and neuronal injury markers as proposed by the National Institute of Ageing-Alzheimer Association criteria offers the most accurate prognosis.</s><s>For clinical trials, selection of subjects in the National Institute of Ageing-Alzheimer Association high Alzheimer's disease likelihood group or the International Working Group-2 prodromal Alzheimer's disease group could be considered.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>In recent years three sets of research criteria for diagnosis of Alzheimer's disease in subjects with mild cognitive impairment (MCI) have been proposed: the International Working Group (IWG)-1 <ref type="bibr" target="#b5">(Dubois et al., 2007</ref><ref type="bibr" target="#b6">(Dubois et al., , 2010))</ref>, IWG-2 <ref type="bibr" target="#b7">(Dubois et al., 2014)</ref>, and National Institute of Ageing-Alzheimer Association (NIA-AA) criteria <ref type="bibr" target="#b0">(Albert et al., 2011)</ref>.</s><s>The criteria include biomarkers of Alzheimer's disease pathology to increase the confidence that subjects with MCI have Alzheimer's disease as underlying cause.</s><s>However, they differ in the definition of MCI and biomarker abnormality <ref type="bibr" target="#b26">(Visser et al., 2012)</ref> (Table <ref type="table" target="#tab_0">1</ref>).</s><s>A direct comparison between the criteria is lacking and it remains unclear which criteria are best to use.</s></p><p><s>The IWG criteria use the term prodromal Alzheimer's disease for diagnosis of Alzheimer's disease and were designed to serve as research criteria.</s><s>The IWG-1 criteria require episodic memory impairment and at least one abnormal Alzheimer's disease biomarker.</s><s>This biomarker can be a topographical marker [i.e.</s><s>medial temporal lobe atrophy on MRI or parieto-temporal hypoperfusion on 18 Ffluorodeoxyglucose (FDG)-PET] or a pathophysiological marker (i.e.</s><s>decreased CSF amyloid-b 1-42 , increased CSF tau, or increased amyloid PET uptake) <ref type="bibr" target="#b5">(Dubois et al., 2007</ref><ref type="bibr" target="#b6">(Dubois et al., , 2010))</ref>.</s><s>The updated IWG-2 criteria require cognitive impairment in any cognitive domain and either both decreased CSF amyloid-b 1-42 and increased tau, or increased amyloid PET uptake <ref type="bibr" target="#b7">(Dubois et al., 2014)</ref>.</s><s>These criteria specify two subtypes: typical prodromal Alzheimer's disease if impairment on a memory test is present; and atypical prodromal Alzheimer's if only impairment on a non-memory test is present.</s><s>The NIA-AA criteria use the term 'mild cognitive impairment due to Alzheimer's disease' and were designed for both clinical and research use.</s><s>They require cognitive impairment in any cognitive domain and abnormal amyloid markers (i.e.</s><s>decreased CSF amyloid-b 1-42 or increased amyloid PET uptake) or neuronal injury markers (i.e.</s><s>medial temporal lobe atrophy on MRI, increased CSF tau, or parietotemporal hypoperfusion on FDG-PET).</s><s>They relate the number of abnormal biomarkers to the likelihood that MCI is due to Alzheimer's disease <ref type="bibr" target="#b0">(Albert et al., 2011)</ref> (Table <ref type="table" target="#tab_0">1</ref>).</s></p><p><s>Preliminary studies have shown that the IWG-1 and NIA-AA criteria have a fair to good predictive ability for progression to Alzheimer's disease-type dementia in subjects with MCI <ref type="bibr" target="#b4">(Bouwman et al., 2010;</ref><ref type="bibr" target="#b17">Oksengard et al., 2010;</ref><ref type="bibr" target="#b19">Petersen et al., 2013;</ref><ref type="bibr" target="#b20">Prestia et al., 2013)</ref>.</s><s>The validity of the IWG-2 criteria has not yet been tested.</s><s>The aim of the present study is to compare the IWG-1, IWG-2 and NIA-AA criteria on prevalence and outcome of Alzheimer's disease at the MCI stage by means of a large multicentre study.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Material and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subjects</head><p><s>Subjects were recruited from five multicentre studies: DESCRIPA <ref type="bibr" target="#b25">(Visser et al., 2008)</ref>, AddNeuroMed <ref type="bibr" target="#b12">(Lovestone et al., 2009)</ref>, German Dementia Competence Network (DCN; <ref type="bibr" target="#b11">Kornhuber et al., 2009)</ref>, the European Alzheimer's Disease Consortium (EADC)-PET <ref type="bibr" target="#b15">(Morbelli et al., 2012)</ref>, and American Alzheimer's Disease Neuroimaging Initiative (ADNI-1) study <ref type="bibr" target="#b16">(Mueller et al., 2005</ref>; Supplementary material); and from eight centres of the EADC: Amsterdam (van der <ref type="bibr" target="#b22">Flier et al., 2014)</ref>, Antwerp <ref type="bibr" target="#b23">(Van der Mussele et al., 2014)</ref>, Brescia <ref type="bibr" target="#b9">(Frisoni et al., 2009)</ref>, Coimbra <ref type="bibr" target="#b2">(Baldeiras et al., 2008)</ref>, Gothenburg <ref type="bibr" target="#b8">(Eckerstro ¨m et al., 2010)</ref>, Kuopio (Seppa ¨la ¨et al., 2011), Lie `ge <ref type="bibr" target="#b3">(Bastin et al., 2010)</ref>, and Lisbon <ref type="bibr" target="#b13">(Maroco et al., 2011)</ref>.</s><s>If a subject participated in more than one study, we used data from the study with the longest follow-up.</s></p><p><s>Inclusion criteria of the present study were diagnosis of MCI, availability of at least one of the following biomarkers: amyloid-b 1-42 and tau in CSF, qualitative or quantitative measures of medial temporal lobe atrophy on MRI [visual rating scale (medial temporal lobe atrophy score) or hippocampal volume], or cerebral glucose metabolism on brain FDG-PET; and at least one clinical follow-up assessment.</s><s>Exclusion criteria were diagnosis of dementia at baseline or any other vascular, somatic, psychiatric or neurological disorder that might have caused the cognitive impairment.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical assessment</head><p><s>Clinical assessment was performed according to the routine protocol at each site, including a clinical interview, Mini-Mental State Examination scoring, and neuropsychological assessment.</s><s>Baseline diagnosis of MCI was made according to the criteria of <ref type="bibr" target="#b18">Petersen et al. (2004)</ref>.</s><s>Raw scores on neuropsychological tests were converted to Z-scores at each centre.</s><s>Cognitive impairment was defined as Z-score 5 À 1.5 standard deviation (SD) on at least one cognitive test (Supplementary Table <ref type="table" target="#tab_0">1</ref>).</s><s>Subjects with a Z-score 5 À 1.5 SD on a memory test were classified as having amnestic MCI.</s><s>Subjects with a Z-score 5 À 1.5 SD on a non-memory test only were classified as having non-amnestic MCI.</s></p><p><s>Primary outcome measures were the proportion of subjects with Alzheimer's disease at the MCI stage based on the IWG-1, IWG-2 and NIA-AA criteria and progression to Alzheimer's disease-type dementia according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition <ref type="bibr">(APA, 1994)</ref> and National Institute of Neurological and Communicative Disorders and Stroke -Alzheimer's Disease and Related Disorders Association criteria <ref type="bibr" target="#b14">(McKhann et al., 1984)</ref>.</s><s>Secondary outcome measure was cognitive decline on the Mini-Mental State Examination.</s></p><p><s>The medical ethics committee at each centre approved the study.</s><s>All subjects provided informed consent.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Biomarker assessment</head><p><s>Biomarker assessment was performed according to the routine protocol at each site.</s><s>PET scans were rated centrally.</s><s>We used centre-specific cut-offs to define abnormal biomarkers (Supplementary Table <ref type="table" target="#tab_1">2</ref>).</s><s>Visual assessments of medial temporal lobe atrophy on MRI and cerebral glucose metabolism on FDG-PET were performed by experienced clinicians who were blinded to clinical and CSF biomarker data.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subject classification</head><p><s>According to the IWG-1 criteria, subjects were classified as 'prodromal Alzheimer's disease' if they had episodic memory impairment and at least one abnormal biomarker.</s><s>This could be a topographical or pathophysiological marker (Table <ref type="table" target="#tab_0">1</ref>).</s><s>Although the IWG-1 criteria recommended a cued recall test to define memory impairment, such tests were not available for most studies and we used non-cued memory tests as well.</s><s>According to the IWG-1 update of 2010, we defined atypical prodromal Alzheimer's disease as non-amnestic MCI with abnormal biomarkers in a post hoc analysis.</s></p><p><s>According to the IWG-2 criteria, subjects were classified as 'prodromal Alzheimer's disease' if they had impairment in memory (typical prodromal Alzheimer's disease) or nonmemory domains (atypical prodromal Alzheimer's disease) and abnormal CSF amyloid-b 1-42 and tau biomarkers (Table <ref type="table" target="#tab_0">1</ref>).</s><s>In the main analysis we pooled typical and atypical prodromal Alzheimer's disease but we also performed analyses for each subgroup separately.</s></p><p><s>According to the NIA-AA criteria, we distinguished between amyloid (i.e.</s><s>CSF amyloid-b 1-42 ) and neuronal injury markers (i.e.</s><s>CSF tau, cerebral glucose metabolism on FDG-PET, medial temporal lobe atrophy score or hippocampal volume).</s><s>Subjects with MCI in any domain were classified in the low Alzheimer's disease likelihood group if both amyloid and neuronal injury markers were normal, in the high Alzheimer's disease likelihood group if amyloid and at least one neuronal injury marker were abnormal, and in one of the two conflicting biomarker groups if the amyloid marker was abnormal and neuronal injury markers normal [isolated amyloid pathology group (IAP)] or if at least one neuronal injury marker was abnormal and the amyloid marker normal [suspected non-Alzheimer pathophysiology group (SNAP)] <ref type="bibr" target="#b10">(Jack et al., 2012;</ref><ref type="bibr" target="#b19">Petersen et al., 2013;</ref><ref type="bibr">Vos et al., 2013a)</ref>.</s><s>Of the subjects who had only one biomarker available, subjects were classified in the intermediate Alzheimer's disease likelihood group if the marker that was tested was abnormal and in the uninformative/inconclusive group if the marker was tested normal (Table <ref type="table" target="#tab_0">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analyses</head><p><s>Statistical analyses were done with SPSS version 20.0 with significance set at P 5 0.05.</s><s>Baseline differences between</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Sample demographics</head><p><s>We included 1607 subjects with a mean follow-up of 2.4 years (SD 1.3, range 0.5-9).</s><s>One thousand five hundred and eleven subjects had a 1-year follow-up, 1069 a 2-year follow-up, 594 a 3-year follow-up, 170 a 4-year follow-up, 70 a 5-year follow-up, and 44 subjects had a follow-up longer than 5 years.</s><s>Seven hundred and sixty-six subjects had data on amyloid and neuronal injury markers (CSF amyloid-b 1-42 with CSF tau, medial temporal lobe, or FDG-PET) and 841 subjects had data on only a neuronal injury marker (medial temporal lobe n = 698; FDG-PET n = 143).</s><s>Supplementary Tables <ref type="table" target="#tab_3">3 and 4</ref> show the number of subjects for each biomarker by centre and the characteristics for the total sample and separate biomarker groups.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Prevalence and outcome</head><p><s>Table <ref type="table" target="#tab_1">2</ref> shows the classification and characteristics of subjects according to the criteria and Table <ref type="table" target="#tab_2">3</ref> shows the outcome according to the criteria classification.</s><s>Eight hundred and fifty (53%) subjects had prodromal Alzheimer's disease according to the IWG-1 criteria, and 308 (40%) subjects according to the IWG-2 criteria, either typical or atypical (Table <ref type="table" target="#tab_1">2</ref>).</s><s>Subjects with prodromal Alzheimer's disease were more likely to progress to Alzheimer's disease-type dementia (Table <ref type="table" target="#tab_2">3</ref> and Fig. <ref type="figure" target="#fig_1">1</ref>) and showed a larger decline on the Mini-Mental State Examination (Supplementary Table <ref type="table" target="#tab_4">5</ref> and Supplementary Fig. <ref type="figure" target="#fig_1">1</ref>) than subjects without prodromal Alzheimer's disease.</s></p><p><s>According to the NIA-AA criteria, of the subjects with amyloid and injury markers available, 353 (46%) subjects were classified in the high Alzheimer's disease likelihood group, 49 (6%) in the IAP group, 220 (29%) in the SNAP group, and 144 (19%) in the low Alzheimer's disease likelihood group (Table <ref type="table" target="#tab_1">2</ref>).</s><s>Of the subjects with only a neuronal injury marker available, 459 (55%) were classified in the intermediate Alzheimer's disease likelihood group and 382 (45%) in the inconclusive group.</s><s>Subjects in the high Alzheimer's disease likelihood group were more likely to progress to Alzheimer's disease-type dementia than subjects in all other groups (Table <ref type="table" target="#tab_2">3</ref> and Fig. <ref type="figure" target="#fig_1">1</ref>).</s><s>When the NIA-AA categories were dichotomized, subjects with high Alzheimer's disease likelihood had a higher progression rate compared to subjects in the low Alzheimer's disease likelihood and conflicting biomarker groups and subjects in the high Alzheimer's disease likelihood and conflicting biomarker groups had a higher progression rate than subjects in the low Alzheimer's disease likelihood group (Supplementary Table <ref type="table" target="#tab_4">5</ref>).</s><s>The high and intermediate Alzheimer's disease likelihood groups showed a larger decline on the Mini-Mental State Examination compared to all other groups (Supplementary Table <ref type="table" target="#tab_5">6</ref> and Supplementary Fig. <ref type="figure" target="#fig_1">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Head-to-head comparison of criteria</head><p><s>In the subgroup of subjects with both amyloid and injury markers (n = 766), the Cox regression prediction model showed a slightly better fit for the NIA-AA criteria than for the IWG-2 and IWG-1 criteria because the À2 log-likelihood or deviance (a measure for unexplained variance) was lowest for the NIA-AA criteria (2906 versus 2926 and 2982, respectively).</s><s>Table <ref type="table" target="#tab_3">4</ref> shows the overlap in classification between the criteria by outcome after 3 years.</s><s>The requirement of memory impairment for IWG-1 prodromal Alzheimer's disease and the requirement of abnormal CSF amyloid-b 1-42 and tau markers for IWG-2 prodromal Alzheimer's disease resulted in differences in classification compared to the NIA-AA criteria.</s><s>Furthermore, the NIA-AA conflicting biomarker groups are considered prodromal Alzheimer's disease according to the IWG-1 criteria but not according to the IWG-2 criteria.</s><s>In subsequent analyses, we dichotomized the NIA-AA criteria in two ways: (i) high Alzheimer's disease likelihood group versus conflicting and low Alzheimer's disease likelihood groups; and (ii) high Alzheimer's disease likelihood and conflicting groups versus low Alzheimer's disease likelihood group.</s><s>Table <ref type="table" target="#tab_4">5</ref> shows that the specificity and positive predictive value were highest for IWG-2, whereas the sensitivity and negative predictive value were highest for NIA-AA (ii).</s><s>NIA-AA (i) showed the highest Youden index.</s></p><p><s>In the subgroup of subjects with only a neuronal injury marker (n = 841), the Cox regression model fit was slightly better for IWG-1 ( À2 log-likelihood 3000) than for NIA-AA ( À2 log-likelihood 3012).</s><s>The specificity was higher for IWG-1 than NIA-AA (Table <ref type="table" target="#tab_4">5</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Typical versus atypical Alzheimer's disease</head><p><s>Of the subjects without IWG-1 prodromal Alzheimer's disease, subjects with non-amnestic MCI and abnormal  biomarkers (atypical prodromal Alzheimer's disease according to the IWG-1 update, n = 231) were more likely to progress to Alzheimer's disease-type dementia (3-year progression rate 31%) than subjects with amnestic or nonamnestic MCI with normal biomarkers (n = 526, 3-year progression 17%, hazard ratio = 1.9, 95% CI 1.3-2.7,</s><s>P 5 0.0001; Supplementary Fig. <ref type="figure" target="#fig_2">2</ref>).</s><s>Subjects with IWG-2 atypical prodromal Alzheimer's disease (n = 49) had a similar progression rate as subjects with IWG-2 typical prodromal Alzheimer's disease (n = 259; 3-year progression rate 63 versus 61%, P = 0.78; Supplementary Fig. <ref type="figure" target="#fig_2">2</ref>).</s></p><p><s>Progression to non-Alzheimer's disease dementia Using the IWG-2 criteria, progression to non-Alzheimer's disease dementia was higher for subjects without prodromal Alzheimer's disease than for subjects with prodromal Alzheimer's disease (Table <ref type="table" target="#tab_1">2</ref>; 3-year progression rate 13% versus 3%; hazard ratio = 3.4, 1.3-8.8,</s><s>P = 0.011).</s><s>Using the NIA-AA classification, progression to non-Alzheimer's disease dementia was higher in the low Alzheimer's disease likelihood (3-year progression The low Alzheimer's disease likelihood group represents subjects with normal amyloid and neuronal injury markers, the high Alzheimer's disease likelihood group represents subjects with both abnormal amyloid and neuronal injury markers, the IAP group is a conflicting biomarker group with an abnormal amyloid marker and normal neuronal injury marker, the SNAP group is a conflicting biomarker group with an abnormal neuronal injury marker and normal amyloid marker, the intermediate Alzheimer's disease likelihood group represents subjects with an abnormal neuronal injury marker without information on amyloid pathology, the inconclusive group represents subjects with a normal neuronal injury marker without information on amyloid pathology.</s><s>AD = Alzheimer's disease.</s><s>rate 14%) and SNAP (3-year progression 13%) groups compared to the high Alzheimer's disease likelihood and inconclusive groups (3-year progression both 4%; Table <ref type="table" target="#tab_1">2</ref>; low: hazard ratio = 3.0, 1.3-6.9,</s><s>P = 0.011 compared to high, hazard ratio = 2.8, 1.2-6.5,</s><s>P = 0.016 compared to inconclusive; SNAP: hazard ratio = 2.6, 1.2-5.6,</s><s>P = 0.013 compared to high, hazard ratio = 2.5, 1.1-5.3,</s><s>P = 0.021 compared to inconclusive).</s><s>Using the IWG-1 criteria, no difference in progression to non-Alzheimer's disease dementia was found between subjects without and with prodromal Alzheimer's disease (Table <ref type="table" target="#tab_1">2</ref>; 3-year progression rate 8% versus 7%; hazard ratio = 1.2, 0.8-1.9,</s><s>P = 0.35).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Effect of neuronal injury marker</head><p><s>Subject classification based on an amyloid marker in combination with CSF tau or with medial temporal lobe was generally the same (Table <ref type="table" target="#tab_5">6</ref>).</s><s>Of the subjects with an abnormal amyloid marker and two neuronal injury markers, 29% had only one injury marker abnormal, with tau being more often abnormal than the medial temporal lobe (Table <ref type="table" target="#tab_6">7</ref>).</s><s>Both these neuronal injury groups had a similar outcome.</s><s>Subjects with abnormal CSF amyloid-b 1-42 and both abnormal CSF tau and medial temporal lobe atrophy had a higher progression rate to Alzheimer's disease-type dementia than those with only one abnormal neuronal injury marker (68% versus 36-41%, P 5 0 .0001).</s><s>Similar findings were obtained in subjects with a normal amyloid marker (Table <ref type="table" target="#tab_6">7</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>SNAP characterization</head><p><s>Because the SNAP group showed a relatively high progression rate to Alzheimer's disease-type dementia, we investigated CSF amyloid-b 1-42 levels between subjects with and without progression by comparing how much amyloidb 1-42 levels were above the cut-off.</s><s>Analyses were restricted to subjects for whom biomarkers were analysed by ELISA (n = 185), as the number of subjects with suspected  Results are predictive accuracy for Alzheimer's disease-type dementia after 3-year follow-up according to the criteria for the subgroup with amyloid and neuronal injury markers (n = 766) and for the subgroup with only a neuronal injury marker (n = 841).</s><s>For the IWG-1 and IWG-2 criteria, groups are defined as no prodromal Alzheimer's disease versus prodromal Alzheimer's disease.</s><s>Youden index = sensitivity + specificity À1.</s></p><p><s>non-Alzheimer pathophysiology for whom biomarkers were analysed by xMAP was relatively small (n = 35).</s><s>Subjects with SNAP who progressed to Alzheimer's disease-type dementia had amyloid-b 1-42 levels closer to the cut-off than subjects who did not progress and subjects who progressed to non-Alzheimer's disease dementia [158 (SD 142) above the cut-off versus 336 (SD 257) and 381 (SD 259) pg/ml above the cut-off, P 5 0.0001; Fig. <ref type="figure" target="#fig_2">2</ref>].</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>This is the first large-scale multicentre study to compare the IWG-1, IWG-2 and NIA-AA criteria for prodromal Alzheimer's disease in subjects with MCI.</s><s>We noted marked differences between the criteria in Alzheimer's disease prevalence and predictive accuracy for Alzheimer's disease-type dementia.</s></p><p><s>The IWG criteria were designed to identify individuals with a high probability of having Alzheimer's disease for research purposes.</s><s>Indeed, we found relatively high progression rates for Alzheimer's disease-type dementia in subjects with prodromal Alzheimer's disease but we found also that a substantial part of the subjects not meeting prodromal Alzheimer's disease criteria progressed to Alzheimer's disease-type dementia.</s><s>For the IWG-1 criteria, we demonstrated that the high progression rate in subjects without prodromal Alzheimer's disease is likely due to the presence of subjects with non-amnestic MCI with abnormal biomarkers.</s><s>For the IWG-2 criteria, we demonstrated that this is likely due to the inclusion of subjects with IAP and SNAP in this group.</s><s>A remarkable finding was the similar predictive accuracy of IWG-2 typical and atypical prodromal Alzheimer's disease.</s><s>This corroborates a previous   study <ref type="bibr">(Vos et al., 2013b)</ref> and supports the use of nonamnestic MCI as Alzheimer's disease clinical phenotype.</s></p><p><s>The NIA-AA criteria were designed both for research and clinical purposes.</s><s>The prognosis of the low, high and intermediate Alzheimer's disease likelihood subgroups nicely fitted with the proposed terminology.</s></p><p><s>In the subsample with both amyloid and neuronal injury markers available, differences in sensitivity, specificity, positive predictive value, and negative predictive value between the criteria can be explained by whether one or two biomarkers needed to be abnormal.</s><s>If both were required to be abnormal (as was the case for IWG-2 and NIA-AA high Alzheimer's disease likelihood versus low Alzheimer's disease likelihood and conflicting biomarker groups), positive predictive value and specificity were high and sensitivity and negative predictive value low, consistent with previous findings (van <ref type="bibr">Rossum et al., 2012)</ref>.</s><s>If one biomarker was required abnormal (as was the case for IWG-1, NIA-AA high Alzheimer's disease-likelihood and conflicting biomarker groups versus low-Alzheimer's disease-likelihood group), predictive value and specificity were low and sensitivity and negative predictive value high.</s></p><p><s>In the subsample with only a neuronal injury marker available, the higher specificity for IWG-1 compared to NIA-AA (intermediate Alzheimer's disease likelihood group versus inconclusive group) likely reflects the requirement of memory impairment for IWG-1 prodromal Alzheimer's disease.</s><s>The progression rate to Alzheimer's disease-type dementia in the NIA-AA intermediate Alzheimer's disease likelihood group was similar to that of the high Alzheimer's disease likelihood group and suggests that many subjects also had abnormal amyloid markers</s></p><p><s>The relatively high progression rate ($20%) for subjects with SNAP is intriguing, as the biomarker profile suggests that non-Alzheimer's disease pathology is likely <ref type="bibr" target="#b19">(Petersen et al., 2013)</ref>.</s><s>We found that subjects with SNAP who progressed to Alzheimer's disease-type dementia had CSF amyloid-b 1-42 levels just above the cut-off.</s><s>This indicates that the amyloid-b 1-42 cut-offs may have been too conservative, although using a more lenient cut-off would also lead to more false positives.</s><s>Alternatively, it could be that these subjects have comorbidities so that less amyloid pathology is needed to progress to Alzheimer's disease-type dementia.</s><s>SNAP could also be an atypical form of Alzheimer's disease with less pronounced amyloid pathology.</s><s>It is also possible that these subjects have non-Alzheimer's disease pathology with minimal amyloid deposits and are misclassified as Alzheimer's disease-type dementia at follow-up.</s></p><p><s>Only a small group of subjects was classified in the IAP group, likely because most subjects with Alzheimer's disease already have neuronal injury at the MCI stage.</s><s>Approximately 20% of the subjects with IAP progressed to Alzheimer's disease-type dementia.</s><s>A previous MCI study did not find any converters with IAP, although this could be due to their relatively short follow-up (1 year; <ref type="bibr" target="#b19">Petersen et al., 2013)</ref>.</s><s>Studies with longer follow-up are needed to see whether all subjects with IAP will eventually progress to Alzheimer's disease-type dementia or have some amyloid pathology unrelated to Alzheimer's disease.</s></p><p><s>Availability of only one biomarker is a common clinical situation.</s><s>As amyloid assessment is relatively invasive and expensive, often only neuronal injury markers will be measured.</s><s>In subjects with only injury markers, the prognostic accuracy of the NIA-AA intermediate Alzheimer's disease likelihood and inconclusive groups was very similar to that of the IWG-1 groups.</s></p><p><s>A higher progression rate to non-Alzheimer's disease dementia was found in subjects without IWG-2 prodromal Alzheimer's disease compared to those with prodromal Alzheimer's disease and in subjects in the NIA-AA low Alzheimer's disease likelihood and SNAP groups compared to the high Alzheimer's disease likelihood group.</s><s>This is inline with what is expected based on the biomarker profiles.</s><s>In general, the progression rate to non-Alzheimer's disease dementia at follow-up was rather low, which could be because the cohorts were designed to study Alzheimer's disease.</s></p><p><s>We found that 29% of the subjects with abnormal CSF amyloid-b 1-42 and two neuronal injury markers (CSF tau and MTL) had only one of the abnormal injury markers.</s><s>This is likely because the neuronal injury biomarkers measure different pathophysiologies, and abnormality in one does not always mean that the other is abnormal as well, at least at the MCI stage.</s><s>Subjects with both abnormal injury markers had higher Alzheimer's disease progression rates compared to those with only one abnormal injury marker in combination with amyloid pathology.</s><s>This is in-line with previous studies <ref type="bibr" target="#b21">(Scott et al., 2010;</ref><ref type="bibr" target="#b24">van Rossum et al., 2012)</ref> and suggests that the former group is further in the disease process or has a more aggressive form of Alzheimer's disease.</s></p><p><s>The lack of standardized biomarker cut-offs is a known drawback in the field.</s><s>We applied centre-specific biomarker cut-offs to correct for possible differences in lab procedures.</s><s>Use of the same CSF ELISA cut-off for all centres would have led to essentially the same results (Supplementary Table <ref type="table" target="#tab_6">7</ref>).</s><s>Although the use of predefined cut-offs likely resulted in somewhat lower sensitivities and specificities compared to other studies that used cut-offs defined within the sample, our study may better reflect the real diagnostic accuracy of biomarkers/the criteria.</s></p><p><s>This study has several limitations.</s><s>Because the findings were based on memory clinic or research populations, they may not be generalizable to other settings.</s><s>For some subjects a MRI assessment was not performed or data were not provided to us, although this is normally part of clinical routine.</s><s>No autopsy data were available, which might have led to misclassification of Alzheimer's disease.</s><s>Furthermore, we used retrospective data so centres used different cognitive tests and biomarker protocols.</s><s>Although this reflects current clinical practice, it could have introduced variability.</s><s>Analyses for the largest cohorts separately showed some variability in prevalence and outcome of Alzheimer's disease in subjects with MCI (Supplementary Tables <ref type="table">8 and 9</ref>).</s><s>However, as this variability is typically random, pooling data from all centres is likely to balance out on average.</s><s>Furthermore, as our main aim was to compare the sets of criteria, variability in operationalization will affect each of the criteria similarly.</s><s>Standardization of cognitive tests and biomarkers will be an important goal to achieve in the future and many initiatives have started working on this.</s><s>But even after standardization the criteria may still perform differently in specific settings.</s><s>Because we used retrospective data, access to tests that measure non-memory domains was limited.</s><s>Our operationalization of atypical prodromal Alzheimer's disease may therefore not entirely reflect the clinical variants described in the IWG-2 criteria and may be less sensitive to detect atypical cognitive profiles.</s><s>While the IWG-1 criteria recommended a cued recall test to define memory impairment, such tests were not available for most studies and we used non-cued memory tests as well.</s><s>New prospective studies should include a wider range of cognitive tests to improve operationalization of the criteria.</s><s>We used CSF amyloid-b 1-42 as amyloid marker while use of amyloid-PET could have led to different results and would be interesting in light of the IWG-2 criteria.</s><s>The major strengths of our study include the large sample size of well-characterized subjects and relatively long follow-up.</s></p><p><s>Our findings have several implications.</s><s>Although the IWG-1, IWG-2 and NIA-AA criteria for prodromal Alzheimer's disease can all be used to select subjects for therapeutic trials or clinical follow-up, as they all predict cognitive decline with reasonable accuracy, a certain set of criteria may be preferred for specific purposes.</s><s>In clinical trials, a high conversion rate is needed.</s><s>If both amyloid and neuronal injury markers are available, one could best select subjects according to the IWG-2 prodromal Alzheimer's disease group or NIA-AA high Alzheimer's disease likelihood group.</s><s>This means that subjects with any MCI can be included.</s><s>If only neuronal injury markers are available, the IWG-1 criteria should be considered rather than the NIA-AA criteria because of the higher specificity due to requirement of amnestic MCI for prodromal Alzheimer's disease.</s><s>In clinical settings, a refined prognosis is needed and exclusion of the disease is important to reassure patients.</s><s>The NIA-AA criteria will then offer the most accurate prognosis.</s><s>As Alzheimer's disease at the MCI stage can manifest as non-memory impairment, a broad definition of MCI should be applied.</s></p><p><s>IAP and SNAP are heterogeneous conditions with subgroups progressing to Alzheimer's disease-type dementia and further studies are needed to characterize these subjects' prognosis and underlying pathophysiology.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc><div><p><s>mean (SD) for continuous variables or frequency (%).</s><s>MMSE = Mini-Mental State Examination (range 0-30) APOE genotype was only available in a subgroup of the sample: IWG-1 no prodromal Alzheimer's disease n = 593 and prodromal Alzheimer's disease n = 641; IWG-2 no prodromal Alzheimer's disease n = 410 and prodromal Alzheimer's disease n = 289; NIA-AA Low n = 128, High n = 327, IAP n = 48, SNAP n = 196, Intermediate n = 281, Inconclusive n = 254.</s><s>compared to prodromal Alzheimer's disease.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 1</head><label>1</label><figDesc><div><p><s>Figure1Alzheimer's disease-type dementia survival probability by the IWG-1, IWG-2 and NIA-AA criteria.</s><s>The graphs represent the Alzheimer's disease-type dementia survival probability according to the IWG-1 (left), IWG-2 (middle), and NIA-AA (right) criteria, adjusted for age, gender, education and centre.</s><s>IWG-1: The group without prodromal Alzheimer's disease represents subjects without memory impairment and/or abnormal biomarker(s).</s><s>The prodromal Alzheimer's disease group represents subjects with memory impairment and at least one abnormal biomarker.</s><s>IWG-2: The group without prodromal Alzheimer's disease represents subjects with normal CSF amyloid-b 1-42 and/or tau.</s><s>The prodromal Alzheimer's disease group represents subjects with abnormal CSF amyloid-b 1-42 and tau.</s><s>NIA-AA: The low Alzheimer's disease likelihood group represents subjects with normal amyloid and neuronal injury markers, the high Alzheimer's disease likelihood group represents subjects with both abnormal amyloid and neuronal injury markers, the IAP group is a conflicting biomarker group with an abnormal amyloid marker and normal neuronal injury marker, the SNAP group is a conflicting biomarker group with an abnormal neuronal injury marker and normal amyloid marker, the intermediate Alzheimer's disease likelihood group represents subjects with an abnormal neuronal injury marker without information on amyloid pathology, the inconclusive group represents subjects with a normal neuronal injury marker without information on amyloid pathology.</s><s>AD = Alzheimer's disease.</s></p></div></figDesc><graphic coords="7,76.25,286.98,468.92,161.41" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 2</head><label>2</label><figDesc><div><p><s>Figure 2 CSF amyloid-b 1-42 levels above the cut-off in the SNAP group by outcome.</s><s>Results are CSF amyloid-b 1-42 levels above the cut-off of subjects with SNAP who had Alzheimer's disease-type dementia, no dementia or non-Alzheimer's disease dementia at follow-up.</s><s>As amyloid-b 1-42 cut-offs were different for different studies, we compared the amyloid-b 1-42 levels above the cut-off (deviation from the cut-off) and not overall amyloid-b 1-42 levels.</s><s>The bold line represents the mean CSF amyloid-b 1-42 levels above the cut-off.</s><s>AD = Alzheimer's disease, Aß = amyloid-b.</s></p></div></figDesc><graphic coords="9,64.46,401.39,228.46,126.65" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s>Classification according to the IWG-1, IWG-2 and NIA-AA criteria -type dementia.</s><s>The relation of the criteria with change on the Mini-Mental State Examination was assessed by slope analyses with general linear mixed models including the baseline and last follow-up score.</s><s>The model was specified with a random intercept and slope and with centre as a random effect because this model provided the best À2 log-likelihood compared with models with simpler covariance structures.</s><s>All analyses were adjusted for age, gender, education and centre.</s><s>Additionally, we calculated the sensitivity, specificity, positive and negative predictive value, and Youden index (sensitivity + specificity À1) for Alzheimer's disease-type dementia after 3 years.</s></p></div></figDesc><table><row><cell>Criteria</cell><cell>Definition</cell></row><row><cell>IWG-1 (2007)</cell><cell></cell></row><row><cell>No prodromal Alzheimer's disease</cell><cell>No memory impairment or normal biomarkers</cell></row><row><cell>Prodromal Alzheimer's disease</cell><cell>Memory impairment, at least one abnormal Alzheimer's disease biomarker</cell></row><row><cell>IWG-2 (2014)</cell><cell></cell></row><row><cell>No prodromal Alzheimer's disease</cell><cell>Any cognitive impairment, normal CSF amyloid-b 1-42 and/or tau or normal amyloid PET scan a</cell></row><row><cell>Prodromal Alzheimer's disease</cell><cell>Any cognitive impairment, abnormal CSF amyloid-b 1-42 and tau or abnormal amyloid PET scan a</cell></row><row><cell>NIA-AA (2011)</cell><cell></cell></row><row><cell>Low Alzheimer's disease likelihood group</cell><cell>Any cognitive impairment, normal amyloid and neuronal injury markers</cell></row><row><cell>High Alzheimer's disease likelihood group</cell><cell>Any cognitive impairment, abnormal amyloid and neuronal injury markers</cell></row><row><cell>Conflicting IAP group</cell><cell>Any cognitive impairment, abnormal amyloid and normal neuronal injury marker</cell></row><row><cell>Conflicting SNAP group</cell><cell>Any cognitive impairment, normal amyloid and abnormal neuronal injury marker</cell></row><row><cell>Intermediate Alzheimer's disease likelihood group</cell><cell>Any cognitive impairment, one marker tested b and abnormal</cell></row><row><cell>Inconclusive/uninformative group</cell><cell>Any cognitive impairment, one marker tested b and normal</cell></row><row><cell cols="2">Amyloid marker = CSF amyloid-b 1-42; neuronal injury marker = CSF tau/medial temporal lobe atrophy score/hippocampal volume/FDG-PET, cognitive impairment is defined as</cell></row><row><cell>Z-score 5 À1.5.</cell><cell></cell></row><row><cell>a In our study, CSF data are used for subject classification.</cell><cell></cell></row><row><cell>b In our study, only neuronal injury markers were tested.</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2</head><label>2</label><figDesc><div><p><s>Demographics and clinical outcome according to the IWG-1, IWG-2 and NIA-AA criteria</s></p></div></figDesc><table><row><cell></cell><cell>Uninformative/</cell><cell>inconclusive</cell><cell></cell><cell>Amyloid?</cell><cell>Injury À</cell><cell>n = 382</cell><cell></cell><cell></cell><cell cols="2">69.0 (8.4) L,H,A,I</cell><cell>232 (61%) L,H,A,B,I</cell><cell>10.3 (4.8) H</cell><cell>259 (68%) H,I</cell><cell></cell><cell>2.4 (1.4) I</cell><cell>89 (35%) H,I</cell><cell>27.6 (2.2) H,B,I</cell><cell>26.2 (4.0) H,I</cell><cell>68 (18%) L,H,I</cell><cell></cell><cell></cell><cell></cell><cell>2.7 (1.5) I</cell><cell></cell><cell></cell><cell>11 (3%) L,B</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>3</cell></row><row><cell></cell><cell>Intermediate</cell><cell>Alzheimer's</cell><cell>disease likelihood</cell><cell>Amyloid? Injury +</cell><cell>n = 459</cell><cell></cell><cell></cell><cell></cell><cell cols="2">72.8 (7.3) L,H,A,B,U</cell><cell>223 (49%) U</cell><cell>10.7 (4.4) H</cell><cell>379 (83%) L,A,B,U</cell><cell></cell><cell>2.2 (1.3) A,B,U</cell><cell>144 (51%) L,H,B,U</cell><cell>26.7 (2.2) L,H,A,U</cell><cell>24.2 (3.8) L,H,A,B,U</cell><cell>201 (44%) L,H,A,B,U</cell><cell></cell><cell></cell><cell></cell><cell>2.3 (1.3) U</cell><cell></cell><cell></cell><cell>26 (6%)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>8</cell></row><row><cell></cell><cell>Conflicting B:</cell><cell>SNAP</cell><cell></cell><cell>Amyloid À</cell><cell>Injury +</cell><cell>n = 220</cell><cell></cell><cell></cell><cell cols="2">69.4 (8.3) L,H,A,I</cell><cell>104 (47%) U</cell><cell>10.5 (4.0) H</cell><cell>148 (67%) H,I</cell><cell></cell><cell>2.5 (1.3) I</cell><cell>62 (32%) H,I</cell><cell>26.7 (2.3) L,H,A,U</cell><cell>25.7 (4.0) L,H,I</cell><cell>47 (21%) L,H,I</cell><cell></cell><cell></cell><cell></cell><cell>2.6 (1.8)</cell><cell></cell><cell></cell><cell>21 (10%) H,U</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>6</cell></row><row><cell></cell><cell>Conflicting A:</cell><cell>IAP</cell><cell></cell><cell>Amyloid +</cell><cell>Injury À</cell><cell>n = 49</cell><cell></cell><cell></cell><cell cols="2">66.1 (7.7) L,H,B,I,U</cell><cell>21 (43%) U</cell><cell>11.0 (4.0)</cell><cell>30 (61%) H,I</cell><cell></cell><cell>2.7 (1.5) I</cell><cell>22 (46%) L,H</cell><cell>27.6 (1.9) H,B,I</cell><cell>26.3 (4.0) H,I</cell><cell>11 (22%) L,H,I</cell><cell></cell><cell></cell><cell></cell><cell>3.1 (1.8)</cell><cell></cell><cell></cell><cell>2 (4%)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>High Alzheimer's</cell><cell>disease</cell><cell>likelihood</cell><cell>Amyloid +</cell><cell>Injury +</cell><cell>n = 353</cell><cell></cell><cell></cell><cell cols="2">71.4 (7.6) L,A,B,I,U</cell><cell>165 (47%) U</cell><cell>11.7 (4.3) L,B,I,U</cell><cell>293 (83%) L,A,B,U</cell><cell></cell><cell>2.3 (1.2)</cell><cell>207 (63%) L,A,B,I,U</cell><cell>26.2 (2.4) L,A,B,I,U</cell><cell>22.5 (4.9) L,A,B,I,U</cell><cell>207 (59%) L,A,B,I,U</cell><cell></cell><cell></cell><cell></cell><cell>2.3 (1.2)</cell><cell></cell><cell></cell><cell>10 (3%) L,B</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>NIA-AA criteria</cell><cell>Low Alzheimer's</cell><cell>disease</cell><cell>likelihood</cell><cell>Amyloid À</cell><cell>Injury À</cell><cell>n = 144</cell><cell></cell><cell></cell><cell cols="2">62.9 (9.0) H,A,B,I,U</cell><cell>63 (44%) U</cell><cell>10.5 (3.2) H</cell><cell>98 (68%) H,I</cell><cell></cell><cell>2.4 (1.1)</cell><cell>36 (28%) H,A,I</cell><cell>27.7 (2.3) H,B,I</cell><cell>27.0 (3.2) H,B,I</cell><cell>5 (4%) H,A,B,I,U</cell><cell></cell><cell></cell><cell></cell><cell>2.9 (1.1)</cell><cell></cell><cell></cell><cell>15 (10%) H,U</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>7</cell></row><row><cell></cell><cell>Prodromal</cell><cell>Alzheimer's</cell><cell>disease</cell><cell>CSF markers +</cell><cell>n = 308</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>71.4 (7.6)</cell><cell>147 (48%)</cell><cell>11.9 (4.1)</cell><cell>259 (84%)</cell><cell></cell><cell>2.3 (1.2)</cell><cell>190 (66%)</cell><cell>26.2 (2.5)</cell><cell>22.4 (5.0)</cell><cell>186 (60%)</cell><cell></cell><cell></cell><cell></cell><cell>2.3 (1.2)</cell><cell></cell><cell></cell><cell>5 (2%)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>IWG-2 criteria</cell><cell>No prodromal</cell><cell>Alzheimer's</cell><cell>disease</cell><cell>CSF markers À</cell><cell>n = 458</cell><cell></cell><cell></cell><cell></cell><cell cols="2">67.2 (8.9) P</cell><cell>206 (45%)</cell><cell>10.6 (3.9) P</cell><cell>310 (68%) P</cell><cell></cell><cell>2.4 (1.3)</cell><cell>137 (33%) P</cell><cell>27.1 (2.3) P</cell><cell>25.8 (3.9) P</cell><cell>84 (18%) P</cell><cell></cell><cell></cell><cell></cell><cell>2.5 (1.7)</cell><cell></cell><cell></cell><cell>43 (9%) P</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>13</cell></row><row><cell></cell><cell>Prodromal</cell><cell>Alzheimer's</cell><cell>disease</cell><cell>Amnestic mild</cell><cell>cognitive</cell><cell>impairment</cell><cell>and at least one</cell><cell>marker +</cell><cell>n = 850</cell><cell>71.3 (7.9)</cell><cell>402 (47%)</cell><cell>11.2 (4.2)</cell><cell>850 (100%)</cell><cell></cell><cell>2.3 (1.3)</cell><cell>342 (53%)</cell><cell>26.4 (2.3)</cell><cell>23.3 (4.5)</cell><cell>405 (48%)</cell><cell></cell><cell></cell><cell></cell><cell>2.3 (1.3)</cell><cell></cell><cell></cell><cell>40 (5%)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>9</cell></row><row><cell>IWG-1 criteria</cell><cell>No prodromal</cell><cell>Alzheimer's</cell><cell>disease</cell><cell>Normal markers</cell><cell>or no amnestic</cell><cell>mild cognitive</cell><cell>impairment</cell><cell>n = 757</cell><cell cols="2">Age, years 68.6 (8.7) P</cell><cell>Female, n 406 (54%) P</cell><cell>Education, years 10.3 (4.4) P</cell><cell>Amnestic mild cognitive 357 (47%) P</cell><cell>impairment, n</cell><cell>Follow-up, years 2.4 (1.3)</cell><cell>APOE-"4 218 (37%) P</cell><cell>MMSE at baseline 27.5 (2.2) P</cell><cell>MMSE at last follow-up 26.2 (3.9) P</cell><cell>Progression to 134 (18%) P</cell><cell>Alzheimer's disease-type</cell><cell>dementia at last</cell><cell>follow-up</cell><cell>Time to Alzheimer's 2.4 (1.3)</cell><cell>disease-type dementia,</cell><cell>years</cell><cell>Progression to 45 (6%)</cell><cell>non-Alzheimer's disease</cell><cell>dementia at last follow-up</cell><cell>Diagnosis of non-Alzheimer's</cell><cell>disease dementia:</cell><cell>Frontotemporal dementia 15</cell><cell>Lewy body dementia</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3</head><label>3</label><figDesc><div><p><s>Alzheimer's disease-type dementia survival probability by the IWG-1, IWG-2 and NIA-AA criteria</s></p></div></figDesc><table><row><cell>3-year progression rate to</cell><cell>Hazard ratio**</cell><cell>P-value</cell></row><row><cell>Alzheimer's disease-type dementia*</cell><cell>(95% CI)</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4</head><label>4</label><figDesc><div><p><s>Overlap in subject classification according to the IWG-1, IWG-2 and NIA-AA criteria by outcome after 3 years</s></p></div></figDesc><table><row><cell></cell><cell>NIA-AA</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell cols="3">Amyloid and neuronal injury markers (n = 766)</cell><cell></cell><cell cols="2">Only a neuronal injury marker (n = 841)</cell></row><row><cell></cell><cell>Low Alzheimer's</cell><cell>High Alzheimer's</cell><cell>Conflicting:</cell><cell>Conflicting:</cell><cell>Intermediate</cell><cell>Uninformative/</cell></row><row><cell></cell><cell>disease likelihood</cell><cell>disease likelihood</cell><cell>IAP</cell><cell>SNAP</cell><cell>Alzheimer's</cell><cell>Inconclusive</cell></row><row><cell></cell><cell>(n = 144)</cell><cell>(n = 353)</cell><cell>(n = 49)</cell><cell>(n = 220)</cell><cell>disease likelihood</cell><cell>(n = 382)</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(n = 459)</cell><cell></cell></row><row><cell>IWG-1 No prodromal</cell><cell>144 (2%)</cell><cell>60 (45%)</cell><cell>19 (11%)</cell><cell>72 (11%)</cell><cell>80 (19%)</cell><cell>382 (12%)</cell></row><row><cell>Alzheimer's disease</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Prodromal</cell><cell>-</cell><cell>293 (49%)</cell><cell>30 (23%)</cell><cell>148 (20%)</cell><cell>379 (39%)</cell><cell>-</cell></row><row><cell>Alzheimer's disease</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>IWG-2 No prodromal</cell><cell>144 (2%)</cell><cell>45 (42%)</cell><cell>49 (18%)</cell><cell>220 (17%)</cell><cell>NA</cell><cell>NA</cell></row><row><cell>Alzheimer's disease</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Prodromal</cell><cell>-</cell><cell>308 (49%)</cell><cell>-</cell><cell>-</cell><cell>NA</cell><cell>NA</cell></row><row><cell>Alzheimer's disease</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="5">Results are total number of subjects (% of subjects with Alzheimer's disease-type dementia after 3 years of follow-up).</cell><cell></cell><cell></cell></row><row><cell>NA = not applicable</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 5</head><label>5</label><figDesc><div><p><s>Predictive accuracy of the IWG-1, IWG-2 and NIA-AA criteria for Alzheimer's disease-type dementia after 3 years</s></p></div></figDesc><table><row><cell>Sample</cell><cell>Sensitivity</cell><cell>Specificity</cell><cell>Positive predictive</cell><cell>Negative predictive</cell><cell>Youden index</cell></row><row><cell></cell><cell></cell><cell></cell><cell>value</cell><cell>value</cell><cell></cell></row><row><cell>Amyloid and neuronal injury markers</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>IWG-1</cell><cell cols="3">0.82 (0.77-0.87) 0.47 (0.43-0.51) 0.38 (0.34-0.43)</cell><cell>0.86 (0.83-0.90)</cell><cell>0.29 (0.22-0.35)</cell></row><row><cell>IWG-2</cell><cell cols="3">0.69 (0.63-0.75) 0.71 (0.67-0.75) 0.49 (0.43-0.55)</cell><cell>0.85 (0.82-0.88)</cell><cell>0.40 (0.33-0.47)</cell></row><row><cell>NIA-AA (i) high versus conflicting/low</cell><cell cols="3">0.77 (0.72-0.83) 0.66 (0.63-0.70) 0.48 (0.43-0.53)</cell><cell>0.88 (0.85-0.91)</cell><cell>0.44 (0.37-0.51)</cell></row><row><cell>NIA-AA (ii) conflicting/high versus low</cell><cell cols="3">0.99 (0.97-1.00) 0.26 (0.22-0.29) 0.35 (0.31-0.39)</cell><cell>0.98 (0.96-1.00)</cell><cell>0.24 (0.20-0.28)</cell></row><row><cell>Only a neuronal injury marker</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>IWG-1</cell><cell cols="3">0.71 (0.64-0.77) 0.63 (0.60-0.67) 0.39 (0.34-0.44)</cell><cell>0.87 (0.83-0.90)</cell><cell>0.34 (0.27-0.41)</cell></row><row><cell>NIA-AA inconclusive versus intermediate</cell><cell cols="3">0.78 (0.72-0.83) 0.53 (0.49-0.57) 0.36 (0.31-0.40)</cell><cell>0.88 (0.84-0.91)</cell><cell>0.31 (0.24-0.38)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 6</head><label>6</label><figDesc><div><p><s>Classification based on amyloid marker and CSF tau or medial temporal lobe neuronal injury marker Results are prevalence and progression rate for subject classifications based on CSF amyloid-b 1-42 and tau versus CSF amyloid-b 1-42 and medial temporal lobe.</s><s>MTL = medial temporal lobe</s></p></div></figDesc><table><row><cell></cell><cell cols="2">IWG-1 criteria</cell><cell cols="2">NIA-AA criteria</cell><cell></cell></row><row><cell></cell><cell>Normal</cell><cell>Amnestic mild</cell><cell>Amyloid À</cell><cell>Amyloid +</cell><cell>Amyloid +</cell><cell>Amyloid À</cell></row><row><cell></cell><cell>group</cell><cell>cognitive impairment</cell><cell>Injury À</cell><cell>Injury +</cell><cell>Injury À</cell><cell>Injury +</cell></row><row><cell></cell><cell></cell><cell>and at least one</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>marker +</cell><cell></cell><cell></cell><cell></cell></row><row><cell>CSF amyloid-b 1-42 and tau, n = 766</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Prevalence</cell><cell cols="2">327 (43%) 439 (57%)</cell><cell>198 (26%)</cell><cell>308 (40%)</cell><cell>94 (12%)</cell><cell>166 (22%)</cell></row><row><cell>Progression to Alzheimer's disease-type dementia</cell><cell cols="2">55 (17%) 215 (49%)</cell><cell>12 (6%)</cell><cell>186 (60%)</cell><cell>32 (34%)</cell><cell>40 (24%)</cell></row><row><cell>at last follow-up</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>CSF amyloid-b 1-42 and MTL, n = 544</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Prevalence</cell><cell cols="2">240 (44%) 304 (56%)</cell><cell>156 (29%)</cell><cell>191 (35%)</cell><cell>102 (19%)</cell><cell>95 (18%)</cell></row><row><cell>Progression to Alzheimer's disease-type dementia</cell><cell cols="2">42 (18%) 158 (52%)</cell><cell>14 (9%)</cell><cell>122 (64%)</cell><cell>28 (28%)</cell><cell>36 (38%)</cell></row><row><cell>at last follow-up</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 7</head><label>7</label><figDesc><div><p><s>Classification based on amyloid marker and two neuronal injury markers</s></p></div></figDesc><table><row><cell>Amyloid marker</cell><cell>Amyloid +</cell><cell>(n = 286)</cell><cell></cell><cell></cell><cell>Amyloid À</cell><cell>(n = 258)</cell><cell></cell><cell></cell></row><row><cell>Neuronal injury markers</cell><cell>Tau À</cell><cell>Tau +</cell><cell>Tau À</cell><cell>Tau +</cell><cell>Tau À</cell><cell>Tau +</cell><cell>Tau À</cell><cell>Tau +</cell></row><row><cell></cell><cell>MTL À</cell><cell>MTL À</cell><cell>MTL +</cell><cell>MTL +</cell><cell>MTL À</cell><cell>MTL À</cell><cell>MTL +</cell><cell>MTL +</cell></row><row><cell>Prevalence within amyloid subgroup</cell><cell>37 (13%)</cell><cell>58 (20%)</cell><cell>25 (9%)</cell><cell cols="2">168 (58%) 91 (35%)</cell><cell>65 (25%)</cell><cell cols="2">39 (15%) 63 (24%)</cell></row><row><cell>Prevalence in total group</cell><cell>37 (7%)</cell><cell>58 (11%)</cell><cell>25 (5%)</cell><cell cols="2">166 (31%) 91 (17%)</cell><cell>65 (12%)</cell><cell>39 (7%)</cell><cell>63 (12%)</cell></row><row><cell>Progression to Alzheimer's disease-type</cell><cell>12 (32%)</cell><cell>24 (41%)</cell><cell>9 (36%)</cell><cell cols="2">113 (68%) 4 (4%)</cell><cell>10 (15%)</cell><cell>5 (13%)</cell><cell>23 (37%)</cell></row><row><cell>dementia at last follow-up</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>Results are prevalence and progression rate for subject classifications based on CSF amyloid-b 1-42 , tau and medial temporal lobe.</s><s>MTL=medial temporal lobe.</s></p></note></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under EMIF grant agreement n 115372, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/ 2007-2013) and EFPIA companies' in kind contribution.</s></p><p><s>This research was performed within the framework of CTMM, The Centre for Translational Molecular Medicine (www.ctmm.nl),</s><s>project .</s></p><p><s>The DESCRIPA study was funded by the European Commission within the 5th framework program (QLRT-2001(QLRT- -2455)).</s></p><p><s>The</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding</head><p><s>This study resulted from a collaboration between centers of the European Alzheimer's Disease Consortium (EADC).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supplementary material</head><p><s>Supplementary material is available at Brain online.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">The diagnosis of mild cognitive impairment due to Alzheimer&apos;s disease: recommendations from the National Institute on Aging and Alzheimer&apos;s Association workgroup</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Albert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Dekosky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Dickson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dubois</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Feldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Fox</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Alzheimers Dement</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="270" to="279" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<monogr>
		<title level="m" type="main">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV</title>
		<imprint>
			<date type="published" when="1994">1994</date>
			<publisher>American Psychiatric Association</publisher>
			<pubPlace>Washington, DC</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">I</forename><surname>Baldeiras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Santana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Proenc ¸a</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Garrucho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Pascoal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rodrigues</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Alzheimers Dis</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="117" to="128" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Controlled memory processes in questionable Alzheimer&apos;s disease: a view from neuroimaging research</title>
		<author>
			<persName><forename type="first">C</forename><surname>Bastin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kerrouche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lekeu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Adam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Guillaume</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lemaire</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Alzheimers Dis</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="547" to="560" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">New research criteria for the diagnosis of Alzheimer&apos;s disease applied in a memory clinic population</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">H</forename><surname>Bouwman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Verwey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Klein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Blankenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Sluimer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dement Geriatr Cogn Disord</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="1" to="7" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Research criteria for the diagnosis of Alzheimer&apos;s disease: revising the NINCDS-ADRDA criteria</title>
		<author>
			<persName><forename type="first">B</forename><surname>Dubois</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Feldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Jacova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Dekosky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Barberger-Gateau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cummings</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Neurol</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="734" to="746" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Revising the definition of Alzheimer&apos;s disease: a new lexicon</title>
		<author>
			<persName><forename type="first">B</forename><surname>Dubois</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Feldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Jacova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Cummings</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Dekosky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Barberger-Gateau</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Neurol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="1118" to="1127" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Advancing research diagnositic criteria for Alzheimer&apos;s disease: the IWG-2 criteria</title>
		<author>
			<persName><forename type="first">B</forename><surname>Dubois</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Feldman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Jacova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hampel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Molinuevo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Blennow</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Neurol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="614" to="629" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Combination of hippocampal volume and cerebrospinal fluid biomarkers improves predictive value in mild cognitive impairment</title>
		<author>
			<persName><forename type="first">C</forename><surname>Eckerstro ¨m</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Andreasson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Olsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rolstad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Blennow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zetterberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dement Geriatr Cogn Disord</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="294" to="300" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Markers of Alzheimer&apos;s disease in a population attending a memory clinic</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">B</forename><surname>Frisoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Prestia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Zanetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Galluzzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Romano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cotelli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Alzheimers Dement</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="307" to="317" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">An operational approach to National Institute on Aging-Alzheimer&apos;s association criteria for preclinical Alzheimer disease</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Jack</surname><genName>Jr</genName></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Knopman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Weigand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Wiste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Vemuri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Lowe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="765" to="775" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Early and differential diagnosis of dementia and mild cognitive impairment. Design and cohort baseline characteristics of the German Dementia Competence Network</title>
		<author>
			<persName><forename type="first">J</forename><surname>Kornhuber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Schmidtke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Froelich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Perneczky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Wolf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hampel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dement Geriatr Cogn Disord</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="404" to="417" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">AddNeuroMed -the European collaboration for the discovery of novel biomarkers for Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">S</forename><surname>Lovestone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Francis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kloszewska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Meccoci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Simmons</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Soininen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann NY Acad Sci</title>
		<imprint>
			<biblScope unit="volume">1180</biblScope>
			<biblScope unit="page" from="36" to="46" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Data mining methods in the prediction of Dementia: a real-data comparison of the accuracy, sensitivity and specificity of Linear Discriminant Analysis, Logistic Regression, Neural Networks, Support Vector Machines, Classification Trees and Random Forests</title>
		<author>
			<persName><forename type="first">J</forename><surname>Maroco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rodrigues</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Guerreiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Santana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>De Mendonc ¸a</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Res Notes</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">299</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Clinical diagnosis of Alzheimer&apos;s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer&apos;s Disease</title>
		<author>
			<persName><forename type="first">G</forename><surname>Mckhann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Drachman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Folstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Katzman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Stadlan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="939" to="944" />
			<date type="published" when="1984">1984</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Resting metabolic connectivity in prodromal Alzheimer&apos;s disease. A European Alzheimer Disease Consortium (EADC) project</title>
		<author>
			<persName><forename type="first">S</forename><surname>Morbelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Drzezga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Perneczky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">B</forename><surname>Frisoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Caroli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">N</forename><surname>Van Berckel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurobiol Aging</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="2533" to="2550" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Ways toward an early diagnosis in Alzheimer&apos;s disease: the Alzheimer&apos;s Disease Neuroimaging Initiative (ADNI)</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Mueller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">W</forename><surname>Weiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Thal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Petersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Jack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Jagust</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Alzheimers Dement</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="55" to="66" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Lack of accuracy for the proposed &apos;Dubois criteria&apos; in Alzheimer&apos;s disease: a validation study from the Swedish brain power initiative</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Oksengard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Cavallin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Axelsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Andersson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Na ¨gga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Winblad</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Dement Geriatr Cogn Disord</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="374" to="380" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Mild cognitive impairment as a diagnostic entity</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Petersen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Intern Med</title>
		<imprint>
			<biblScope unit="volume">256</biblScope>
			<biblScope unit="page" from="183" to="194" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Criteria for mild cognitive impairment due to alzheimer&apos;s disease in the community</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Petersen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Aisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">F</forename><surname>Boeve</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">E</forename><surname>Geda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Ivnik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Knopman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="199" to="208" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Prediction of dementia in mild cognitive impairment patients based on core diagnostic markers for Alzheimer disease</title>
		<author>
			<persName><forename type="first">A</forename><surname>Prestia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Caroli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Van Der Flier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ossenkoppele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Van Berckel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Barkhof</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="page" from="1048" to="1056" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Abeta1-42</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Bartlett</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">C</forename><surname>Fox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Barnes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="825" to="834" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Optimizing Patient Care and Research: the Amsterdam Dementia Cohort</title>
		<author>
			<persName><forename type="first">¨tt</forename><surname>Seppa ¨la</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Koivisto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hartikainen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Helisalmi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Soininen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sk ;</forename><surname>Herukka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">M</forename><surname>Van Der Flier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">A</forename><surname>Pijnenburg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Prins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Lemstra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">H</forename><surname>Bouwman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Teunissen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Alzheimers Dis</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="313" to="327" />
			<date type="published" when="2011">2011. 2014</date>
		</imprint>
	</monogr>
	<note>J Alzheimers Dis</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Behavioral syndromes in mild cognitive impairment and Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">S</forename><surname>Van Der Mussele</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Marie</forename></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Saerens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Somers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Goeman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Deyn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Alzheimers Dis</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="319" to="329" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Injury markers predict cognitive decline in subjects with mild cognitive impairment and amyloid pathology</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">A</forename><surname>Van Rossum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Vos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Burns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Knol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Scheltens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Soininen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="page" from="1809" to="1816" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Development of screening guidelines and clinical criteria for predementia Alzheimer&apos;s disease. The DESCRIPA Study</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Visser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Verhey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Boada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bullock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>De Deyn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">B</forename><surname>Frisoni</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuroepidemiology</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="254" to="265" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Comparison of international working Group criteria and national institute on Aging-Alzheimer&apos;s association criteria for Alzheimer&apos;s disease</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Visser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sjb</forename><surname>Vos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Van Rossum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Scheltens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Alzheimers Dement</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="560" to="563" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Preclinical Alzheimer&apos;s disease and its outcome: a longitudinal cohort study</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Vos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Chengjie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Visser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Jasielec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hassenstab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Grant</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Neurol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="957" to="965" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Prediction of Alzheimer disease in subjects with amnestic and nonamnestic mild cognitive impairment</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Vos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">A</forename><surname>Van Rossum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Verhey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Knol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Soininen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">O</forename><surname>Wahlund</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="page" from="1124" to="1132" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
